Related Experiment Video
Updated: Jun 10, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Revisiting risankizumab: a newer biologic drug in dermatology
Aditya K Bubna1, Vinayak Viplav2
1Department of Dermatology, Katihar Medical College, Al-Karim University, Katihar, India - zimbabwa21@gmail.com.
Introduction:
Risankizumab is an interleukin 23p19 inhibitor, approved by the USA Food and Drug Administration (FDA) for the management of moderate to severe plaque psoriasis. Apart from its utility in psoriasis, there are a number of other dermatologic conditions where risankizumab has demonstrated value. The aim of this narrative review is to describe the utility of risankizumab in psoriasis, as well as its implication in off-label dermatologic disorders.
Evidence Acquisition:
PubMed, Google Scholar, Scopus and ResearchGate were searched for scholarly articles related to risankizumab and its utility in dermatology using the search terms "Risankizumab" AND "Psoriasis" AND "other dermatological disorders."
Evidence Synthesis:
Risankizumab is a valuable biologic agent for the management of psoriasis and psoriatic arthropathy. It has also been used successfully for other dermatologic disorders like hidradenitis suppurativa, pityriasis rubra pilaris and pyoderma gangrenosum.
Conclusions:
Risankizumab's usage is not limited to psoriasis. Its benefit extends to many more dermatologic conditions. Besides, it has an acceptable safety profile.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:43Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...